You are here

Article Text

Article menu
Download PDFPDF
Chest clinic
Audit, research and guideline update
Long-acting β-agonist prescribing in people with asthma in primary care
  1. Daniel R Morales1,
  2. Cathy Jackson2,
  3. Shona Fielding3,
  4. Bruce Guthrie1
  1. 1Population Health Sciences Division, Medical Research Institute, University of Dundee, Dundee, UK
  2. 2School of Medicine, University of St Andrews, Fife, UK
  3. 3Division of Applied Health Sciences, University of Aberdeen, Aberdeen, UK
  1. Correspondence to Dr Daniel R Morales, Population Health Sciences Division, Medical Research Institute, University of Dundee, Mackenzie Building, Dundee DD2 4BF, UK; d.r.z.morales{at}dundee.ac.uk

Abstract

Long-acting β2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

  • Asthma
  • Asthma in primary care
  • Asthma Guidelines

https://doi.org/10.1136/thoraxjnl-2012-202071

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Linked Articles